选择性JAK1抑制剂在类风湿关节炎中药物留存优于泛JAK抑制剂:真实世界证据的Meta分析
该Meta分析纳入7项真实世界观察性研究共21244例类风湿关节炎患者,比较选择性JAK1抑制剂与泛JAK抑制剂的药物留存率。结果显示选择性JAK1抑制剂停药风险显著更低(合并HR 0.72;95%CI 0.61-0.85;p<0.001),主要因疗效不足导致的停药减少,而不良事件和感染相关停药风险两组相似。
要点
- 疗效不足相关停药风险显著降低(HR 0.68)。
- 不良事件和感染相关停药风险两组无显著差异。
核心结论
- 真实世界证据表明,在RA患者中,选择性JAK1抑制剂的药物留存优于泛JAK抑制剂,主要归因于持续疗效而非安全性差异。
研究设计与样本
- 系统检索PubMed、Embase和Cochrane Library截至2025年12月的观察性研究,纳入比较选择性JAK1抑制剂(upadacitinib、filgotinib)与泛JAK抑制剂(tofacitinib、baricitinib)药物留存的注册队列和索赔数据库研究,共纳入7项研究21244例来自欧洲、亚洲和美国的成人RA患者。
主要发现
- 选择性JAK1抑制剂组较泛JAK抑制剂组的总体停药风险显著更低(合并HR 0.72;95%CI 0.61-0.85;p<0.001)。
- 因疗效不足导致的停药风险显著降低(合并HR 0.68;95%CI 0.55-0.84;p<0.01)。
- 因不良事件导致的停药风险两组相似(合并HR 0.91;95%CI 0.75-1.10;p=0.34)。
- 因感染导致的停药风险两组相似(合并HR 1.15;95%CI 0.85-1.55;p=0.40)。
临床怎么用
- 在RA真实世界治疗中,若关注长期药物留存,选择性JAK1抑制剂可能优于泛JAK抑制剂,尤其对于疗效维持需求较高的患者。
局限性
- 纳入研究均为观察性设计,可能存在混杂偏倚;原文摘要未报告异质性、发表偏倚等进一步分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The durability of Janus kinase (JAK) inhibitors in routine clinical practice is still debated. This study aimed to compare the drug retention rates of selective JAK1 inhibitors (upadacitinib, filgotinib) with pan-JAK inhibitors (tofacitinib, baricitinib) in patients with rheumatoid arthritis (RA) using real-world data. METHODS: We conducted a systematic literature search in PubMed, Embase, and the Cochrane Library for observational studies published up to December 2025. The analysis included registry-based cohorts and claims database studies that compared drug retention between selective JAK1 and pan-JAK inhibitors in adult RA patients. The primary outcome was the overall risk of drug discontinuation, with pooled Hazard Ratios (HRs) and 95% Confidence Intervals (CIs) calculated using a random-effects model. RESULTS: Seven studies involving 21,244 patients from Europe, Asia, and the United States met the inclusion criteria. Patients treated with selective JAK1 inhibitors had a significantly lower risk of drug discontinuation compared to those on pan-JAK inhibitors (pooled HR 0.72; 95% CI 0.61-0.85; p < 0.001). Subgroup analyses showed that selective JAK1 inhibitors had a significantly reduced risk of discontinuation due to lack of efficacy (pooled HR 0.68; 95% CI 0.55-0.84; p < 0.01). However, the risks of discontinuation due to adverse events (pooled HR 0.91; 95% CI 0.75-1.10; p = 0.34) and infections (pooled HR 1.15; 95% CI 0.85-1.55; p = 0.40) were similar between the groups. CONCLUSION: Real-world evidence indicates that selective JAK1 inhibitors offer better drug retention than pan-JAK inhibitors in RA patients, primarily due to sustained effectiveness rather than differences in safety profiles.
引用
- Lee YH, Song GG. Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidence. Semin Arthritis Rheum. 2026. PMID: 42034889. doi:10.1016/j.semarthrit.2026.152989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。